



Treatment of Peripheral T-cell Lymphomas

Guest Editor:

Dr. Raphael Koch

Department of Hematology and
Medical Oncology, University of
Göttingen, 37075 Göttingen,
Germany

Deadline for manuscript
submissions:

30 September 2024

Message from the Guest Editor

Dear Colleagues,

peripheral T-cell lymphomas (PTCL) are a clinically and molecularly highly heterogeneous group of rare lymphoid malignancies, that typically share an aggressive clinical behavior and poor prognosis. With current first-line treatment strategies, only a minority of patients can be cured and relapsed-refractory diseases underscore the need for innovative therapeutic strategies.

Over the past decade, molecular studies unraveled distinct pathogenic alterations in subgroups of PTCL, providing a basis for both molecular classification and specific therapies addressing the pivotal biology of these diseases. Indeed, upcoming concepts including targeted inhibitors of crucial oncogenic signaling pathways, epigenetic therapeutics as well as immunotherapeutic approaches show promise. Still, tailoring optimal concepts for patients with PTCL remains a significant challenge.

This special issue will highlight preclinical and clinical research on therapeutic strategies and biomarkers in PTCL.





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI